ap5  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs ap5
    hNeurons lose KCC2 immunoreactivity after exposure to HIV-Tat ± morphine. ( A ) Representative images of hNeuron cultures immunolabeled for MAP2 and KCC2. Loss of KCC2 immunoreactivity can be noted in cells treated with both 50 nM Tat 1-86 and 50 nM Tat 1-86 + morphine. Rescue is seen in 50 nM Tat 1-86 + <t>AP5</t> (scale bar = 50 μm). ( B, C ) The percentage of cells immunoreactive for KCC2. Both 6 h ( B ) and 24 h ( C ) exposure to 50 - 100 nM Tat 1-86 ± morphine results in significant decrease in KCC2 immunoreactivity compared to their respective controls ( † p
    Ap5, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ap5/product/Alomone Labs
    Average 93 stars, based on 5 article reviews
    Price from $9.99 to $1999.99
    ap5 - by Bioz Stars, 2022-12
    93/100 stars

    Images

    1) Product Images from "HIV and opiates dysregulate K+-Cl− cotransporter 2 (KCC2) to cause GABAergic dysfunction in primary human neurons and Tat-transgenic mice"

    Article Title: HIV and opiates dysregulate K+-Cl− cotransporter 2 (KCC2) to cause GABAergic dysfunction in primary human neurons and Tat-transgenic mice

    Journal: Neurobiology of disease

    doi: 10.1016/j.nbd.2020.104878

    hNeurons lose KCC2 immunoreactivity after exposure to HIV-Tat ± morphine. ( A ) Representative images of hNeuron cultures immunolabeled for MAP2 and KCC2. Loss of KCC2 immunoreactivity can be noted in cells treated with both 50 nM Tat 1-86 and 50 nM Tat 1-86 + morphine. Rescue is seen in 50 nM Tat 1-86 + AP5 (scale bar = 50 μm). ( B, C ) The percentage of cells immunoreactive for KCC2. Both 6 h ( B ) and 24 h ( C ) exposure to 50 - 100 nM Tat 1-86 ± morphine results in significant decrease in KCC2 immunoreactivity compared to their respective controls ( † p
    Figure Legend Snippet: hNeurons lose KCC2 immunoreactivity after exposure to HIV-Tat ± morphine. ( A ) Representative images of hNeuron cultures immunolabeled for MAP2 and KCC2. Loss of KCC2 immunoreactivity can be noted in cells treated with both 50 nM Tat 1-86 and 50 nM Tat 1-86 + morphine. Rescue is seen in 50 nM Tat 1-86 + AP5 (scale bar = 50 μm). ( B, C ) The percentage of cells immunoreactive for KCC2. Both 6 h ( B ) and 24 h ( C ) exposure to 50 - 100 nM Tat 1-86 ± morphine results in significant decrease in KCC2 immunoreactivity compared to their respective controls ( † p

    Techniques Used: Immunolabeling

    2) Product Images from "Translocation of CaMKII to dendritic microtubules supports the plasticity of local synapses"

    Article Title: Translocation of CaMKII to dendritic microtubules supports the plasticity of local synapses

    Journal: The Journal of Cell Biology

    doi: 10.1083/jcb.201202058

    Activity-dependent translocation of αCaMKII to dendritic sites near synapses. (A) Hippocampal neuron (12 DIV) expressing mGFP-αCaMKII and mCherry imaged before, during, and after stimulation with 0Mg 2+ /Gly for 5 min. (B, i) Pseudocolor image from dendrite in A. Kymograph (ii–iii) and time-lapse (iv) analyses of the change in the fluorescent intensity ratio (mGFP-αCaMKII/mCherry) over time across the dendrite (i–ii, black line) and across the spine (iii, yellow box, red line). Stimulation period is indicated (Stim). (iv) n = 4 spines and subdendritic regions from the neuron shown in A. Red and white arrows (or brackets) point, respectively, to synaptic and dendritic sites where CaMKII translocated. Bars: (neuron) 10 µm; (dendrite) 5 µm. (C) Normalized ratio (±SEM) of dendritic segment where mGFP-αCaMKII accumulated over total dendritic length after a 5-min 0Mg 2+ /Gly stimulation (Vehicle), in the presence of 50 µM AP5, 1 μM TTX, 10 μM Cd 2+ , or 10 μM CPA. n = 7–24 neurons per condition. *, P
    Figure Legend Snippet: Activity-dependent translocation of αCaMKII to dendritic sites near synapses. (A) Hippocampal neuron (12 DIV) expressing mGFP-αCaMKII and mCherry imaged before, during, and after stimulation with 0Mg 2+ /Gly for 5 min. (B, i) Pseudocolor image from dendrite in A. Kymograph (ii–iii) and time-lapse (iv) analyses of the change in the fluorescent intensity ratio (mGFP-αCaMKII/mCherry) over time across the dendrite (i–ii, black line) and across the spine (iii, yellow box, red line). Stimulation period is indicated (Stim). (iv) n = 4 spines and subdendritic regions from the neuron shown in A. Red and white arrows (or brackets) point, respectively, to synaptic and dendritic sites where CaMKII translocated. Bars: (neuron) 10 µm; (dendrite) 5 µm. (C) Normalized ratio (±SEM) of dendritic segment where mGFP-αCaMKII accumulated over total dendritic length after a 5-min 0Mg 2+ /Gly stimulation (Vehicle), in the presence of 50 µM AP5, 1 μM TTX, 10 μM Cd 2+ , or 10 μM CPA. n = 7–24 neurons per condition. *, P

    Techniques Used: Activity Assay, Translocation Assay, Expressing

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Alomone Labs representative aminergic type toxin
    Panels ( A – N ) ELISA time course of antibody responses to immunisation with veVLP antigens. OD 405nm values displayed are signals generated using a 1 in 500 dilution of neat sera pooled from all individuals in that group. ATX <t>Aminergic-type,</t> CTX type 1A cytotoxin, sNTX short chain neurotoxin, PLA2 group I phospholipase A 2 , _ C core located epitope, _ F finger located epitope. Panel ( O ) Demonstration of proportion of pooled group terminal sera at 1 in 500 dilution, in recognising respective specific epitope versus the VLP, displayed as both difference in OD 405 (ΔOD405) between veVLP and native VLP, and as a percentage proportion of the total IgG response (specific IgG [sIgG]). Results represent triplicate readings, with exceptions stated in Supp. File 4 . Error bars represent ± standard deviation.
    Representative Aminergic Type Toxin, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/representative aminergic type toxin/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    representative aminergic type toxin - by Bioz Stars, 2022-12
    94/100 stars
      Buy from Supplier

    93
    Alomone Labs dl amino 5 phosphonovaleric acid
    hNeurons lose KCC2 immunoreactivity after exposure to HIV-Tat ± morphine. ( A ) Representative images of hNeuron cultures immunolabeled for MAP2 and KCC2. Loss of KCC2 immunoreactivity can be noted in cells treated with both 50 nM Tat 1-86 and 50 nM Tat 1-86 + morphine. Rescue is seen in 50 nM Tat 1-86 + <t>AP5</t> (scale bar = 50 μm). ( B, C ) The percentage of cells immunoreactive for KCC2. Both 6 h ( B ) and 24 h ( C ) exposure to 50 - 100 nM Tat 1-86 ± morphine results in significant decrease in KCC2 immunoreactivity compared to their respective controls ( † p
    Dl Amino 5 Phosphonovaleric Acid, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dl amino 5 phosphonovaleric acid/product/Alomone Labs
    Average 93 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    dl amino 5 phosphonovaleric acid - by Bioz Stars, 2022-12
    93/100 stars
      Buy from Supplier

    Image Search Results


    Panels ( A – N ) ELISA time course of antibody responses to immunisation with veVLP antigens. OD 405nm values displayed are signals generated using a 1 in 500 dilution of neat sera pooled from all individuals in that group. ATX Aminergic-type, CTX type 1A cytotoxin, sNTX short chain neurotoxin, PLA2 group I phospholipase A 2 , _ C core located epitope, _ F finger located epitope. Panel ( O ) Demonstration of proportion of pooled group terminal sera at 1 in 500 dilution, in recognising respective specific epitope versus the VLP, displayed as both difference in OD 405 (ΔOD405) between veVLP and native VLP, and as a percentage proportion of the total IgG response (specific IgG [sIgG]). Results represent triplicate readings, with exceptions stated in Supp. File 4 . Error bars represent ± standard deviation.

    Journal: Scientific Reports

    Article Title: Virus-like particles displaying conserved toxin epitopes stimulate polyspecific, murine antibody responses capable of snake venom recognition

    doi: 10.1038/s41598-022-13376-x

    Figure Lengend Snippet: Panels ( A – N ) ELISA time course of antibody responses to immunisation with veVLP antigens. OD 405nm values displayed are signals generated using a 1 in 500 dilution of neat sera pooled from all individuals in that group. ATX Aminergic-type, CTX type 1A cytotoxin, sNTX short chain neurotoxin, PLA2 group I phospholipase A 2 , _ C core located epitope, _ F finger located epitope. Panel ( O ) Demonstration of proportion of pooled group terminal sera at 1 in 500 dilution, in recognising respective specific epitope versus the VLP, displayed as both difference in OD 405 (ΔOD405) between veVLP and native VLP, and as a percentage proportion of the total IgG response (specific IgG [sIgG]). Results represent triplicate readings, with exceptions stated in Supp. File 4 . Error bars represent ± standard deviation.

    Article Snippet: A representative aminergic-type toxin (muscarinic toxin 3, from D. angusticeps) was bought from Alomone Labs (Israel).

    Techniques: Enzyme-linked Immunosorbent Assay, Generated, Standard Deviation

    hNeurons lose KCC2 immunoreactivity after exposure to HIV-Tat ± morphine. ( A ) Representative images of hNeuron cultures immunolabeled for MAP2 and KCC2. Loss of KCC2 immunoreactivity can be noted in cells treated with both 50 nM Tat 1-86 and 50 nM Tat 1-86 + morphine. Rescue is seen in 50 nM Tat 1-86 + AP5 (scale bar = 50 μm). ( B, C ) The percentage of cells immunoreactive for KCC2. Both 6 h ( B ) and 24 h ( C ) exposure to 50 - 100 nM Tat 1-86 ± morphine results in significant decrease in KCC2 immunoreactivity compared to their respective controls ( † p

    Journal: Neurobiology of disease

    Article Title: HIV and opiates dysregulate K+-Cl− cotransporter 2 (KCC2) to cause GABAergic dysfunction in primary human neurons and Tat-transgenic mice

    doi: 10.1016/j.nbd.2020.104878

    Figure Lengend Snippet: hNeurons lose KCC2 immunoreactivity after exposure to HIV-Tat ± morphine. ( A ) Representative images of hNeuron cultures immunolabeled for MAP2 and KCC2. Loss of KCC2 immunoreactivity can be noted in cells treated with both 50 nM Tat 1-86 and 50 nM Tat 1-86 + morphine. Rescue is seen in 50 nM Tat 1-86 + AP5 (scale bar = 50 μm). ( B, C ) The percentage of cells immunoreactive for KCC2. Both 6 h ( B ) and 24 h ( C ) exposure to 50 - 100 nM Tat 1-86 ± morphine results in significant decrease in KCC2 immunoreactivity compared to their respective controls ( † p

    Article Snippet: hNeuron cultures were treated with HIVsup at 125 - 500 pg/mL [p24] or HIV protein (10 - 100 nM HIV-1 Tat1-86 IIIB (clade B) or 250 pM - 1 nM R5-tropic gp120ADA , X4-tropic gp120IIIB , or dual-tropic gp120 MN; ImmunoDx, Woburn MA) ± 500 nM morphine sulfate for 6 or 24 h. Drug treatments: 10 μM CLP257 (Sigma), 50 μM AP5 (Alomone Labs, Jerusalem IL), 50 nM maraviroc (MVC; BOC Sciences, Shirley, NY) were applied 30 min prior to HIVsup , HIV protein, and morphine for 24 h experiments.

    Techniques: Immunolabeling